Testing of serum atherogenicity in cell cultures: Questionable data published;Bewertung der serumatherogenität in den Zellkulturen: Fragliche Daten veröffentlicht

GMS German Medical Science

Volumn 10, Issue , 2012, Pages

  Jargin, Sergei V ^a  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Atherosclerosis; Cell culture; Cholesterol; Serum

Indexed keywords

ALLIUM SATIVUM;

EID: 84857066284     PISSN: 16123174     EISSN: None     Source Type: Journal    
DOI: 10.3205/000153     Document Type: Letter

References (38)

1. Gebbers JO. Atherosclerosis, cholesterol, nutrition, and statins--a critical review. GMS Ger Med Sci. 2007 Aug 16;5:Doc04. Available from: http://www.egms.de/en/journals/gms/2007-5/000040.shtml
2. Mundo-Sagardía JA, Figueroa Y, Altieri PI, Banchs HL, Escobales N, Crespo MJ. The atherosclerotic plaque. P R Health Sci J. 2008 Sep;27(3):241-6.
3. Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, Kurdanov KA, Khashimov KA, Novikov ID, Smirnov VN. Atherogenicity of blood serum from patients with coronary heart disease. Lancet. 1986 Sep 13;2(8507):595-8. DOI: 10.1016/S0140-6736(86)92426-8
4. Jargin SV. Testing of anti-atherogenic drugs and food components on cell cultures: assessment of reliability. P R Health Sci J. 2010 Mar;29(1):86-7.
5. Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IYu, Martsenyuk ON, Lyakishev AA, Smirnov VN. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res. 1988 Mar;62(3):421-9.
6. Tertov VV, Orekhov AN, Sobenin IA, Gabbasov ZA, Popov EG, Yaroslavov AA, Smirnov VN. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res. 1992 Jul;71(1):218-28.
7. Tertov VV, Orekhov AN, Martsenyuk ON, Perova NV, Smirnov VN. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol. 1989 Jun;50(3):337-47. DOI: 10.1016/0014-4800(89)90043-9
8. Orekhov AN, Baldenkov GN, Tertov VV, Ryong LH, Kozlov SG, Lyakishev AA, Tkachuk VA, Ruda MYa, Smirnov VN. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol. 1988;12 Suppl 6:S66-8. DOI: 10.1097/00005344-198812006-00017
9. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct antiatherosclerosis- related effects of garlic. Ann Med. 1995 Feb;27(1):63-5. DOI: 10.3109/07853899509031938
10. Orekhov AN, Kosykh VA, Repin VS, Smirnov VN. Cell proliferation in normal and atherosclerotic human aorta. II. Autoradiographic observation on deoxyribonucleic acid synthesis in primary cell culture. Lab Invest. 1983 Jun;48(6):749-54.
11. Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN. Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipidlowering agents. Atherosclerosis. 1986 May;60(2):101-10. DOI: 10.1016/0021-9150(86)90002-X
12. Riede UN. Störungen des Stoffwechsels. In: Riede UN, Wehner H, eds. Allgemeine und spezielle Pathologie. Stuttgart, New York: Thieme; 1986. p. 78-124.
13. Orekhov AN, Pivovarova EM, Sobenin IA, Yakushkin VV, Tertov VV. Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil. Drugs. 1992;44 Suppl 1:105-110. DOI: 10.2165/00003495-199200441-00020
14. Escobales N. Testing of anti-atherogenic drugs and food components on cell cultures: assessment of reliability. Author's reply. P R Health Sci J. 2010;29(1):87.
15. Tertov VV, Orekhov AN, Sayadyan KS, Serebrennikov SG, Kacharava AG, Lyakishev AA, Smirnov VN. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis. 1990 Apr;81(3):183-9. DOI: 10.1016/0021-9150(90)90065-Q
16. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008 Oct;200(2):239-46.
17. Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 2011 Jan;20(1):5-13. DOI: 10.1177/0961203310382429
18. Gotto AM Jr. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Trans Am Clin Climatol Assoc. 2011;122:256-89.
19. Kraemer BF, Miller JW. Dyslipidemias. In: Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, eds. Melmon and Morrelli's clinical pharmacology: basic principles in therapeutics. 4th ed. New York: McGraw-Hill; 2000. p. 552-80.
20. Tomasoni L, Sitia S, Borghi C, Cicero AF, Ceconi C, Cecaro F, Morganti A, De Gennaro Colonna V, Guazzi M, Morricone L, Malavazos AE, Marino P, Cavallino C, Shoenfeld Y, Turiel M. Effects of treatment strategy on endothelial function. Autoimmun Rev. 2010 Oct;9(12):840-4. DOI: 10.1016/j.autrev.2010.07.017
21. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med. 2010 Dec;48(12):1685-91. DOI: 10.1515/CCLM.2010.277
22. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev. 2004 Feb;25(1):49-68.
23. Scharnagl H, März W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem. 2005;5(3):233-42. DOI: 10.2174/1568026053544524
24. Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis. 2010 Oct 19;9:119. DOI: 10.1186/1476-511X-9-119
25. Sobenin IA, Andrianova IV, Demidova ON, Gorchakova T, Orekhov AN. Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study. J Atheroscler Thromb. 2008 Dec;15(6):334-8. DOI: 10.5551/jat.E550
26. Berthold HK, Sudhop T. Garlic preparations for prevention of atherosclerosis. Curr Opin Lipidol. 1998 Dec;9(6):565-9. DOI: 10.1097/00041433-199812000-00008
27. Pittler MH, Ernst E. Clinical effectiveness of garlic (Allium sativum). Mol Nutr Food Res. 2007 Nov;51(11):1382-5. DOI: 10.1002/mnfr.200700073
28. Jargin SV. Discussion of Evaluation of cholesterol-lowering and antioxidant properties of sugar cane policosanols in hamsters and humans. Appl Physiol Nutr Metab. 2009 Feb;34(1):75; discussion 76-7. DOI: 10.1139/H08-141
29. Jargin SV. Cell culture as a testing system for lipid-lowering substances. Abstracts of the 3rd Intercontinental Congress of Pathology. May 17-22, 2008, Barcelona, Spain. Virchows Arch. 2008 May;452 Suppl 1:S34.
30. Eskin SG, Sybers HD, Lester JW, Navarro LT, Gotto AM Jr, DeBakey ME. Human smooth muscle cells cultured from atherosclerotic plaques and uninvolved vessel wall. In Vitro. 1981 Aug;17(8):713-8. DOI: 10.1007/BF02628408
31. Brown MS, Goldstein JL, Krieger M, Ho YK, Anderson RG. Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J Cell Biol. 1979 Sep;82(3):597-613. DOI: 10.1083/jcb.82.3.597
32. Goldstein JL, Anderson RG, Buja LM, Basu SK, Brown MS. Overloading human aortic smooth muscle cells with low density lipoprotein-cholesteryl esters reproduces features of atherosclerosis in vitro. J Clin Invest. 1977 Jun;59(6):1196-202. DOI: 10.1172/JCI108744
33. Orekhov AN, Andrianova IV, Rekhter MD, Tertov VV, Andreeva ER, Ragimov SE, Mironov AA. Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis. 1992 Jul;95(1):77-85. DOI: 10.1016/0021-9150(92)90178-J
34. Orekhov AN, Tertov VV, Pivovarova EM. The effects of antihypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. Cardiology. 1998;89(2):111-8. DOI: 10.1159/000006765
35. Orekhov AN. In vitro models of anti-atherosclerotic effects of cardiovascular drugs. Am J Cardiol. 1990 Dec 18;66(21):23I-28I. DOI: 10.1016/0002-9149(90)91260-D
36. Orekhov AN, Andreeva ER, Andrianova IV, Bobryshev YV. Peculiarities of cell composition and cell proliferation in different type atherosclerotic lesions in carotid and coronary arteries. Atherosclerosis. 2010 Oct;212(2):436-43. DOI: 10.1016/j.atherosclerosis.2010.07.009
37. Sobenin IA, Suprun IV, Karagodin VP, Feoktistov AS, Melnichenko AA, Orekhov AN. The interaction of plasma sialylated and desialylated lipoproteins with collagen from the intima and media of uninvolved and atherosclerotic human aorta. J Lipids. 2011;2011:254267. DOI: 10.1155/2011/254267
38. Chappey B, Beyssen B, Foos E, Ledru F, Guermonprez JL, Gaux JC, Myara I. Sialic acid content of LDL in coronary artery disease: no evidence of desialylation in subjects with coronary stenosis and increased levels in subjects with extensive atherosclerosis and acute myocardial infarction: relation between desialylation and in vitro peroxidation. Arterioscler Thromb Vasc Biol. 1998;18(6):876-83.